ArticleSignal transduction and targeted therapy2021
IL4I1-driven AHR signature: a new avenue for cancer therapy.
Article in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8Acta pharmacologica Sinica · 2026Article
- Increased IL4I1 expression predicts poor survival and modulates the immune microenvironment in acute myeloid leukemia.Journal of translational medicine · 2026Article
- Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer.iScience · 2024Article
- Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.Cell death & disease · 2024Article
- Immunometabolism in cancer: basic mechanisms and new targeting strategy.Cell death discovery · 2024Review
- Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation.Discover oncology · 2024Article
- Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies.International journal of nanomedicine · 2024Review
- Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.Research square · 2023Article
- Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.Signal transduction and targeted therapy · 2023Review
- IL4I1-catalyzed tryptophan metabolites mediate the anti-inflammatory function of cytokine-primed human muscle stem cells.Cell death discovery · 2023Article
- High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer.BMC endocrine disorders · 2023Article
- Cancer metabolites: promising biomarkers for cancer liquid biopsy.Biomarker research · 2023Review
- Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer.Biology · 2023Review
- Human Chorionic Gonadotropin-Stimulated Interleukin-4-Induced-1 (IL4I1) Promotes Human Decidualization via Aryl Hydrocarbon Receptor.International journal of molecular sciences · 2023Article
- Tubular aryl hydratocarbon receptor upregulates EZH2 to promote cellular senescence in cisplatin-induced acute kidney injury.Cell death & disease · 2023Article
- Metabolic network-based identification of plasma markers for non-small cell lung cancer.Analytical and bioanalytical chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.